An agreement between the National Nanotechnology Centre (Nanotec), University of Tokyo and iCONM (Innovation Centre of NanoMedicine) will see increased use of nanomedicine technology for cancer therapy, as well as enhancing the expertise of a Thai research team for nanomaterial development in a close collaboration with Japan Bridgestone Corporation.
Wannee Chinsirikul, Nanotec’s executive director under the National Science and Technology Development Agency (NSTDA), said the Thai researcher team discussed ongoing collaboration to develop innovative precision nanomedicine for cancer therapy, in a meeting with researchers from iCONM and University of Tokyo. Nanomedicine-based cancer therapy is one part of a policy for creating a smart health social platform.
The meeting discussed related leading-edge science and technology, with a focus on the developments related to terminating cancer cells by use of a drug delivery system that uses nanoparticles to store the drug. By this means, the treatment precisely attacks the cancer cells, with highly positive results and fewer side effects for patients.
“We have agreed to exchange researchers from both institutes to boost cooperation on health and medicine development,” Wannee said. “Progress was made after the Thai Minister of Science and Technology made a visit to iCONM last year.” The bilateral collaboration on nanotechnology development will be very useful for medical science in Thailand, she added.
Moreover, Nanotec’s executives, researchers and private companies met with Japan Bridgestone Cooperation company. They focused on nanomaterial development to improve services for various industry sectors and on increasing product value, together with environmental protection from recycling technology.
“Nanocoating is one example that could be applied for solar cells, as well as other products. It is also useful for soft robotic research and development, especially the development of polymer and rubber for increasing a robot’s flexibility. That technology could be further developed for artificial organs in the future,” she added.
Other research by Carbano regarding adjusting the structure of radioactive materials to bring them in line with industry’s requirements, is done based on nanotechnology.
The Nanotec team was led by Professor Dr Pairash Thajchayapong, chairman of Nanotec executive board, last month attended the 1st University of Tokyo-iCONM-Nanotec Joint Research Meeting on Precision Nanomedicine hosted by the University of Tokyo and the Innovation Centre of NanoMedicine (iCONM).